Welcome to the e-CCO Library!

OP29: ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Loris Riccardo Lopetuso
Created: Tuesday, 28 May 2019, 3:32 PM
Ulcerative colitis, Colorectal cancer, Epithelial cell, Immunology, Mesenchymal cell
Files: 1
OP29: Tofacitinib in Ulcerative Colitis: Real world evidence from Eneida Registry
Year: 2020
Source: ECCO'20 Vienna
Authors: Maria Chaparro
Created: Tuesday, 23 June 2020, 5:40 PM
OP29: Tofacitinib in Ulcerative Colitis: Real world evidence from Eneida Registry
Year: 2020
Source: ECCO'20 Vienna
Authors: Maria Chaparro
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
OP30 The interplay of microbiome dysbiosis and immune system deregulation in patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N.S. Seyed Tabib1, C. Caenepeel1, K. Machiels1, S. Verstockt1, B. Verstockt1,2, N. Ardeshir Davani1, J. Sabino1,2, M. Ferrante1,2, S. Vermeire1,2

Created: Thursday, 30 January 2020, 10:12 AM
OP30: Endothelial cell-mediated smooth muscle hyperplasia in Crohn’s disease intestinal strictures: Caveolin 1 as a potential therapeutic target
Year: 2024
Source: ECCO'24 Stockholm
Authors: Santacroce, Giovanni
Created: Tuesday, 30 April 2024, 5:03 PM
OP30: Human umbilical cord mesenchymal stem cells derived exosomes alleviate Ulcerative Colitis by inhibiting macrophage ferroptosis via miR-23b-3p/Nrf2 pathway
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Liu, L.(1)*;Zhao, J.(1);Ye, Y.(1);Feng, Z.(1);Wang, X.(1);Cao, X.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP30: Lyophilised orally administered faecal microbiota transplantation for Active Ulcerative Colitis (LOTUS study)
Year: 2021
Source: ECCO'21 Virtual
Authors: Haifer, C.(1);Saikal, A.(2);Paramsothy, S.(1);Borody, T.J.(3);Ghaly, S.(2);Kaakoush, N.O.(4);Leong, R.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
OP30: Lyophilised orally administered faecal microbiota transplantation for Active Ulcerative Colitis (LOTUS study)
Year: 2021
Source: ECCO'21 Virtual
Authors: Craig Haifer
Created: Friday, 1 October 2021, 12:41 PM
Background

Faecal microbiota transplantation (FMT) administered via the lower GI tract effectively induces remission in ulcerative colitis (UC). Orally administered FMT capsules may improve patient tolerability and facilitate maintenance therapy while it is unclear if pre-FMT antibiotics enhance therapeutic efficacy.

Methods

We performed a dual-centre randomised, double blind, placebo-controlled trial of oral lyophilised FMT in adults with mild-moderately active UC (total Mayo 4-10). All subjects received 2-weeks of pre-FMT antibiotics (amoxycillin, metronidazole and doxycycline) before 1:1 randomisation to either oral FMT (0.35g stool content per capsule from 1 of 2 healthy donors) or identical placebo for 8 weeks. Enforced tapering and cessation of corticosteroids was mandated. The primary endpoint was week 8 steroid-free clinical remission with endoscopic remission or response (total Mayo score ≤2 with subscores ≤ 1 for rectal bleeding, stool frequency and endoscopic appearance, and ≥1-point reduction from baseline in endoscopy subscore). Responders to FMT induction were re-randomised to either continue maintenance FMT or withdrawal of FMT with final outcomes assessed at week 56.

Results

Recruitment was paused due to the COVID-19 pandemic. 37 patients were randomised. Baseline patient and disease characteristics were balanced between the randomised groups. The primary outcome was achieved in 8/16 (50%) receiving FMT versus 3/19 (16%) receiving placebo (OR: 4.63; 95%CI: 1.74-12.30; P=0.002). Steroid-free clinical remission rates and endoscopic remission rates were 69% vs 26% (P=0.012) and 44% vs 16% (P=0.074) in the FMT and placebo arms, respectively. Reported SAE were worsening colitis (2 FMT, 1 placebo) and PR bleeding relating to previous anal surgery (placebo). Ten patients entered the maintenance withdrawal study. Steroid-free clinical, endoscopic and histologic remission was achieved in 4/4 patients who continued daily oral FMT, with all 6 patients randomised to FMT withdrawal having a flare of disease with a median time to relapse of 6 months.

Conclusion

Oral lyophilised FMT following antibiotic pre-treatment for mild-moderately active ulcerative colitis was associated with a significant increased rate of clinical remission with endoscopic remission or response versus antibiotic treatment alone at week 8. Pre-treatment antibiotics had an additive impact upon treatment efficacy compared with previous studies utilising FMT. Maintenance FMT therapy was associated with sustained clinical, endoscopic and histologic remission at week 56. Treatment was well tolerated and there were no new safety signals related to FMT therapy.

OP30: Serum proteomic profiling predicts and diagnoses pouchitis in ulcerative colitis patients undergoing ileal pouch-anal anastomosis
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Kathleen Machiels
Created: Tuesday, 28 May 2019, 3:32 PM
ANCA, ASCA, other serum markers, Colectomy, Ileo anal pouch procedure, Pouchitis, Proteomics
Files: 1
OP30: Serum proteomic profiling predicts and diagnoses pouchitis in ulcerative colitis patients undergoing ileal pouch-anal anastomosis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Machiels*1, M. Ferrante1,2, N. Davani1, A. Wolthuis3, A. D’Hoore3, S. Vermeire1,2

Created: Friday, 22 February 2019, 9:41 AM
OP30: Upadacitinib modulates inflammatory pathways in gut tissue in patients with Ulcerative Colitis: Transcriptomic profiling from the Phase 2b study, U-ACHIEVE
Year: 2022
Source: ECCO'22
Authors: Verstockt, B.(1);Blink Polakow, S.(2);Mahi, N.(2);Lee, J.(2);Wang, J.(3);Guay, H.(4);Salas, A.(5);Panés, J.(5);Ungaro, R.C.(6);Vermeire, S.(1);
Created: Friday, 11 February 2022, 3:52 PM
OP31 Meta–omics reveals microbiome-driven proteolysis as a contributing factor to the severity of ulcerative colitis disease activity
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Mills1, P. Dulai2, Y. Vázquez-Baeza3, Q. Zhu3, G. Humphrey3, L. DeRight Goldasich3, R. Quinn4, A. Gewirtz5, B. Chassaing5, H. Chu6, W. Sandborn2, P. Dorrestein1, R. Knight3, D. Gonzalez1

Created: Thursday, 30 January 2020, 10:12 AM
OP31: Dietary and Multi-Omic characterization of new onset treatment naive Crohn Disease identifies factors that may contribute to disease pathogenesis
Year: 2022
Source: ECCO'22
Authors: Haberman Ziv, Y.(1);Braun, T.(1);Amir, A.(1);Levhar , N.(1);Malik, A.(1);Neuman, S.(1);Picard, O.(1);Yavzuri, M.(1);Efroni, G.(1);Hadar, R.(1);Ben-Horin, S.(1);
Created: Friday, 11 February 2022, 3:52 PM
OP31: High fat diet exacerbates colitis through microbial metabolite deoxycholic acids induced-ferroptosis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Chen Wang
Created: Friday, 14 July 2023, 2:22 PM
OP31: High fat diet exacerbates colitis through microbial metabolite deoxycholic acids induced-ferroptosis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Wang, C.(1)*;Gu, Y.(1);Cao, H.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP31: Meta–omics reveals microbiome driven proteolysis as a contributing ractor to severity of Ulcerative Colitis disease activity
Year: 2020
Source: ECCO'20 Vienna
Authors: Parambir Dulai
Created: Tuesday, 23 June 2020, 5:40 PM
OP31: Meta–omics reveals microbiome driven proteolysis as a contributing ractor to severity of Ulcerative Colitis disease activity
Year: 2020
Source: ECCO'20 Vienna
Authors: Parambir Dulai
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
OP31: RESTORE: Interim analysis of a Phase 2 study of QBECO SSI for the induction and maintenance of clinical and endoscopic remission in subjects with Moderate to Severe Crohn’s Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Bressler, B.(1);Marshall, J.K.(2);Atkinson, K.(3);Sutcliffe, S.(4);Pankovich, J.(4);Jones, M.(4);Kalyan, S.(4);Gunn, H.(4)
Created: Wednesday, 2 June 2021, 4:12 PM
OP31: Single-cell analyses identify immune and stromal signatures of perianal fistulizing Crohn's Disease
Year: 2024
Source: ECCO'24 Stockholm
Authors: Deepak, Parakkal
Created: Tuesday, 30 April 2024, 5:03 PM